SK14892002A3 - Prípravok majúci mobilizačbú aktivitu - Google Patents

Prípravok majúci mobilizačbú aktivitu Download PDF

Info

Publication number: SK14892002A3
Authority: SK; Slovakia
Prior art keywords: defibrotide; csf; hematopoietic; capacity; progenitors
Prior art date: 2000-04-18

Application number

SK1489-2002A

Other languages

English (en)

Slovak (sk)

Inventor

Laura Ferro

Roberto Porta

Massimo Iacobelli

Alessandro Masimo Gianni

Carmelo Carlo Stella

Original Assignee

Gentium Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-04-18

Filing date

2001-04-10

Publication date

2003-06-03

2001-04-10 Application filed by Gentium Spa filed Critical Gentium Spa

2003-06-03 Publication of SK14892002A3 publication Critical patent/SK14892002A3/sk

Links

230000003394 haemopoietic effect Effects 0.000 title claims abstract description 51
JNWFIPVDEINBAI-UHFFFAOYSA-N [5-hydroxy-4-[4-(1-methylindol-5-yl)-5-oxo-1H-1,2,4-triazol-3-yl]-2-propan-2-ylphenyl] dihydrogen phosphate Chemical compound C1=C(OP(O)(O)=O)C(C(C)C)=CC(C=2N(C(=O)NN=2)C=2C=C3C=CN(C)C3=CC=2)=C1O JNWFIPVDEINBAI-UHFFFAOYSA-N 0.000 title claims abstract description 47
229960004120 defibrotide Drugs 0.000 title claims abstract description 46
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 title claims abstract description 34
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 title claims abstract description 34
239000000203 mixture Substances 0.000 title claims description 21
230000003213 activating effect Effects 0.000 title 1
210000000130 stem cell Anatomy 0.000 claims abstract description 21
238000000034 method Methods 0.000 claims abstract description 17
241000124008 Mammalia Species 0.000 claims abstract description 14
210000005259 peripheral blood Anatomy 0.000 claims abstract description 13
239000011886 peripheral blood Substances 0.000 claims abstract description 13
230000017531 blood circulation Effects 0.000 claims description 7
239000013543 active substance Substances 0.000 claims description 2
239000007864 aqueous solution Substances 0.000 claims description 2
239000000546 pharmaceutical excipient Substances 0.000 claims description 2
239000000126 substance Substances 0.000 claims 1
230000002123 temporal effect Effects 0.000 abstract description 4
230000004087 circulation Effects 0.000 abstract description 3
241000699670 Mus sp. Species 0.000 description 16
241001465754 Metazoa Species 0.000 description 7
210000004369 blood Anatomy 0.000 description 7
239000008280 blood Substances 0.000 description 7
239000004480 active ingredient Substances 0.000 description 6
238000009472 formulation Methods 0.000 description 6
210000000265 leukocyte Anatomy 0.000 description 6
241000699666 Mus <mouse, genus> Species 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
241000282693 Cercopithecidae Species 0.000 description 4
210000004027 cell Anatomy 0.000 description 4
230000000694 effects Effects 0.000 description 4
210000002960 bfu-e Anatomy 0.000 description 3
102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 2
101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 2
102000004890 Interleukin-8 Human genes 0.000 description 2
108090001007 Interleukin-8 Proteins 0.000 description 2
102000036693 Thrombopoietin Human genes 0.000 description 2
108010041111 Thrombopoietin Proteins 0.000 description 2
238000004820 blood count Methods 0.000 description 2
210000001185 bone marrow Anatomy 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
238000000605 extraction Methods 0.000 description 2
210000003714 granulocyte Anatomy 0.000 description 2
239000003102 growth factor Substances 0.000 description 2
210000003958 hematopoietic stem cell Anatomy 0.000 description 2
238000001802 infusion Methods 0.000 description 2
XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 2
229940096397 interleukin-8 Drugs 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
230000008569 process Effects 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
208000009304 Acute Kidney Injury Diseases 0.000 description 1
101100388551 Caenorhabditis elegans glt-3 gene Proteins 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108010008212 Integrin alpha4beta1 Proteins 0.000 description 1
108010002386 Interleukin-3 Proteins 0.000 description 1
102100039064 Interleukin-3 Human genes 0.000 description 1
241000282553 Macaca Species 0.000 description 1
241000282560 Macaca mulatta Species 0.000 description 1
241001529936 Murinae Species 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
241000288906 Primates Species 0.000 description 1
208000033626 Renal failure acute Diseases 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
-1 alkali metal salt Chemical class 0.000 description 1
238000011316 allogeneic transplantation Methods 0.000 description 1
230000002785 anti-thrombosis Effects 0.000 description 1
238000010876 biochemical test Methods 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
230000002301 combined effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
230000003828 downregulation Effects 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
230000036449 good health Effects 0.000 description 1
230000002489 hematologic effect Effects 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
108010044426 integrins Proteins 0.000 description 1
102000006495 integrins Human genes 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
239000003446 ligand Substances 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000001617 migratory effect Effects 0.000 description 1
230000001483 mobilizing effect Effects 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
210000003887 myelocyte Anatomy 0.000 description 1
208000031225 myocardial ischemia Diseases 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
108091033319 polynucleotide Proteins 0.000 description 1
102000040430 polynucleotide Human genes 0.000 description 1
239000002157 polynucleotide Substances 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Hematology (AREA)
Diabetes (AREA)
Molecular Biology (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Peptides Or Proteins (AREA)

SK1489-2002A 2000-04-18 2001-04-10 Prípravok majúci mobilizačbú aktivitu SK14892002A3 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP00830293A EP1147777A1 (en)	2000-04-18	2000-04-18	Combination of defibrotide and G-CSF and its use to activate haematopoietic progenitors
PCT/EP2001/004105 WO2001078761A2 (en)	2000-04-18	2001-04-10	Mixture of defibrotide and g-csf ant its use for activating haematopoietic progenitors

Publications (1)

Publication Number	Publication Date
SK14892002A3 true SK14892002A3 (sk)	2003-06-03

Family

ID=8175292

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1489-2002A SK14892002A3 (sk)	2000-04-18	2001-04-10	Prípravok majúci mobilizačbú aktivitu

Country Status (31)

Country	Link
US (1)	US20040131588A1 (is)
EP (3)	EP1147777A1 (is)
JP (1)	JP5205668B2 (is)
KR (1)	KR100849491B1 (is)
CN (1)	CN1183962C (is)
AT (2)	ATE310532T1 (is)
AU (2)	AU5832201A (is)
BG (1)	BG107203A (is)
CA (1)	CA2406179C (is)
CY (1)	CY1104971T1 (is)
CZ (1)	CZ20023426A3 (is)
DE (2)	DE60140015D1 (is)
DK (2)	DK1276497T3 (is)
EE (1)	EE200200596A (is)
ES (2)	ES2252227T3 (is)
HR (1)	HRP20020835A2 (is)
HU (1)	HUP0300560A3 (is)
IL (1)	IL152328A (is)
IS (1)	IS2171B (is)
MX (1)	MXPA02010346A (is)
NO (1)	NO20024988L (is)
NZ (1)	NZ522016A (is)
PL (1)	PL358100A1 (is)
PT (1)	PT1621207E (is)
RO (1)	RO121006B1 (is)
RU (1)	RU2248216C2 (is)
SI (1)	SI21079B (is)
SK (1)	SK14892002A3 (is)
UA (1)	UA73566C2 (is)
WO (1)	WO2001078761A2 (is)
ZA (1)	ZA200208413B (is)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8771663B2 (en)	2000-04-18	2014-07-08	Gentium Spa	Formulation having mobilising activity
PL1660115T3 (pl) *	2003-07-29	2011-11-30	Dompe Spa	Farmaceutyczna kombinacja G-CSF i PLGF użyteczna wobec komórek macierzystych krwi
JP2007535479A (ja)	2003-08-13	2007-12-06	チルドレンズホスピタルメディカルセンター	ＧＴＰａｓｅを調節するためのキメラペプチド
US7417026B2 (en)	2003-08-13	2008-08-26	Children's Hospital Medical Center	Mobilization of hematopoietic cells
EP2103689A1 (en) *	2008-03-19	2009-09-23	Gentium S.p.A.	Synthetic phosphodiester oligonucleotides and therapeutical uses thereof
RU2376985C1 (ru) *	2008-07-17	2009-12-27	Владислав Николаевич Ласкавый	Средство для активации стволовых клеток
EP2637672B1 (en)	2010-11-12	2018-08-22	Gentium S.r.l.	Defibrotide for use in prophylaxis and/or treatment of graft versus host disease (gvhd).
CA2874960C (en)	2012-06-22	2021-05-18	Gentium S.P.A.	Euglobulin-based method for determining the biological activity of defibrotide
EP3026122A1 (en)	2014-11-27	2016-06-01	Gentium S.p.A.	Cellular-based method for determining the potency of defibrotide
CN106567694A (zh) *	2016-11-14	2017-04-19	北京国泰通源技术有限公司	智能控水短节
RU2758487C2 (ru) *	2018-01-12	2021-10-28	Селлмиг Биолабс Инк.	Способы получения цитокапсул и цитокапсулярных трубок
CN114730031B (zh)	2019-11-13	2024-04-12	富士胶片株式会社	装饰膜、成型物及电子器件

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3899481A (en)	1970-11-03	1975-08-12	Crinos Industria Farmaco	Process for the controlled partial degradation of deoxyribonucleic acid extracted from animal organs
DE2154279A1 (de) *	1970-11-03	1972-05-25	Crinos Industria Farmaco	Medikamente für das fibrinolytische System
IT1043823B (it) *	1970-11-03	1980-02-29	Prephar	Procedimento per l estrazione di acidi nucleici da organi animali
IT1206341B (it)	1984-02-16	1989-04-14	Crinos Industria Farmaco	Composizione farmaceutica per il trattamento dell'ischemia acuta del miocardio.
US4694134A (en)	1985-05-28	1987-09-15	Ajax Magnethermic Corporation	Apparatus for overheating edges of skelp for the production of compression welded pipe
US5223609A (en) *	1986-04-17	1993-06-29	Crinos Industria Farmacobiologica S.P.A.	Process for obtaining chemically defined and reproducible polydeoxyribonucleotides
IT1190313B (it)	1986-04-17	1988-02-16	Crinos Industria Farmaco	Procedimento per l'ottenimento di polidesossiribonucleotidi chimicamente definiti e riproducibili e prodotto farmacologicamente attivo risultante
IT1223322B (it) *	1987-10-23	1990-09-19	Crinos Industria Farmaco	Metodo per prevenire la formazione di coaguli sanguigni nel circuito extracorporeo di apparecchi di dialisi a composizione utile per esso
JP2907447B2 (ja) *	1988-08-24	1999-06-21	中外製薬株式会社	抗血栓剤
IT1231509B (it) *	1989-09-07	1991-12-07	Crinos Industria Farmaco	Composizione farmceutica ad uso topico per la terapia della fragilita' capillare.
US5199942A (en) *	1991-06-07	1993-04-06	Immunex Corporation	Method for improving autologous transplantation
US5977083A (en) *	1991-08-21	1999-11-02	Burcoglu; Arsinur	Method for using polynucleotides, oligonucleotides and derivatives thereof to treat various disease states
JP3021906B2 (ja) *	1992-01-28	2000-03-15	松下電器産業株式会社	電動調理機
RU2136667C1 (ru) *	1995-04-18	1999-09-10	Научно-исследовательский институт фармакологии РАМН	Производные 2-меркаптобензимидазола, обладающие противоишемической, антиаритмической и противофибрилляторной активностью
JPH08127539A (ja) *	1994-10-31	1996-05-21	Ajinomoto Co Inc	ヒトｉｌ−１１を含有する末梢血幹細胞増加剤
EP0801076A4 (en) *	1994-11-30	1999-12-15	Chugai Pharmaceutical Co Ltd	THROMBOCYTOTIC FACTOR
CA2260014A1 (en) *	1996-07-10	1998-01-15	Meiji Milk Products Co., Ltd.	Novel use of mk family as hematopoietic factor
WO1999026639A1 (en) *	1997-11-26	1999-06-03	Allegheny University Of The Health Sciences	Methods for mobilizing hematopoietic facilitating cells and hematopoietic stem cells into the peripheral blood
US6573372B2 (en) *	1999-01-07	2003-06-03	Heska Corporation	Feline immunoglobulin E molecules and compositions there of

2000
- 2000-04-18 EP EP00830293A patent/EP1147777A1/en not_active Withdrawn
2001
- 2001-04-10 DE DE60140015T patent/DE60140015D1/de not_active Expired - Lifetime
- 2001-04-10 AT AT01931582T patent/ATE310532T1/de active
- 2001-04-10 EP EP01931582A patent/EP1276497B1/en not_active Expired - Lifetime
- 2001-04-10 AU AU5832201A patent/AU5832201A/xx active Pending
- 2001-04-10 CA CA2406179A patent/CA2406179C/en not_active Expired - Fee Related
- 2001-04-10 DK DK01931582T patent/DK1276497T3/da active
- 2001-04-10 HU HU0300560A patent/HUP0300560A3/hu unknown
- 2001-04-10 CN CNB018082025A patent/CN1183962C/zh not_active Expired - Fee Related
- 2001-04-10 EE EEP200200596A patent/EE200200596A/xx unknown
- 2001-04-10 HR HR20020835A patent/HRP20020835A2/xx not_active Application Discontinuation
- 2001-04-10 KR KR1020027013967A patent/KR100849491B1/ko not_active Expired - Fee Related
- 2001-04-10 NZ NZ522016A patent/NZ522016A/en unknown
- 2001-04-10 MX MXPA02010346A patent/MXPA02010346A/es active IP Right Grant
- 2001-04-10 DK DK05108424.2T patent/DK1621207T3/da active
- 2001-04-10 SI SI200120022A patent/SI21079B/sl not_active IP Right Cessation
- 2001-04-10 AU AU2001258322A patent/AU2001258322B2/en not_active Ceased
- 2001-04-10 CZ CZ20023426A patent/CZ20023426A3/cs unknown
- 2001-04-10 AT AT05108424T patent/ATE443524T1/de active
- 2001-04-10 US US10/432,741 patent/US20040131588A1/en not_active Abandoned
- 2001-04-10 DE DE60115222T patent/DE60115222T2/de not_active Expired - Lifetime
- 2001-04-10 ES ES01931582T patent/ES2252227T3/es not_active Expired - Lifetime
- 2001-04-10 SK SK1489-2002A patent/SK14892002A3/sk unknown
- 2001-04-10 JP JP2001576061A patent/JP5205668B2/ja not_active Expired - Fee Related
- 2001-04-10 RO ROA200201305A patent/RO121006B1/ro unknown
- 2001-04-10 IL IL152328A patent/IL152328A/en active IP Right Grant
- 2001-04-10 PL PL01358100A patent/PL358100A1/xx not_active Application Discontinuation
- 2001-04-10 ES ES05108424T patent/ES2335776T3/es not_active Expired - Lifetime
- 2001-04-10 WO PCT/EP2001/004105 patent/WO2001078761A2/en not_active Ceased
- 2001-04-10 PT PT05108424T patent/PT1621207E/pt unknown
- 2001-04-10 EP EP05108424A patent/EP1621207B1/en not_active Expired - Lifetime
- 2001-04-10 RU RU2002130719/15A patent/RU2248216C2/ru not_active IP Right Cessation
- 2001-10-04 UA UA2002119177A patent/UA73566C2/uk unknown
2002
- 2002-10-14 IS IS6581A patent/IS2171B/is unknown
- 2002-10-16 NO NO20024988A patent/NO20024988L/no not_active Application Discontinuation
- 2002-10-17 ZA ZA200208413A patent/ZA200208413B/en unknown
- 2002-10-17 BG BG107203A patent/BG107203A/bg unknown
2006
- 2006-02-08 CY CY20061100179T patent/CY1104971T1/el unknown

Also Published As

Publication number	Publication date
IL152328A (en)	2009-12-24
ES2335776T3 (es)	2010-04-05
US20040131588A1 (en)	2004-07-08
SI21079A (sl)	2003-06-30
NO20024988D0 (no)	2002-10-16
JP5205668B2 (ja)	2013-06-05
DK1621207T3 (da)	2010-02-01
WO2001078761A2 (en)	2001-10-25
KR20030010603A (ko)	2003-02-05
RO121006B1 (ro)	2006-11-30
RU2248216C2 (ru)	2005-03-20
PL358100A1 (en)	2004-08-09
DK1276497T3 (da)	2006-03-27
IL152328A0 (en)	2003-05-29
PT1621207E (pt)	2009-12-28
NZ522016A (en)	2004-10-29
CN1434719A (zh)	2003-08-06
CA2406179A1 (en)	2001-10-25
ATE443524T1 (de)	2009-10-15
EP1276497A2 (en)	2003-01-22
HRP20020835A2 (en)	2005-10-31
ZA200208413B (en)	2003-10-17
DE60115222T2 (de)	2006-08-10
ATE310532T1 (de)	2005-12-15
EP1621207A2 (en)	2006-02-01
CZ20023426A3 (cs)	2003-05-14
DE60115222D1 (de)	2005-12-29
EP1276497B1 (en)	2005-11-23
EP1147777A1 (en)	2001-10-24
CA2406179C (en)	2012-03-27
EP1621207B1 (en)	2009-09-23
IS2171B (is)	2006-11-15
DE60140015D1 (de)	2009-11-05
AU2001258322B2 (en)	2006-03-16
CN1183962C (zh)	2005-01-12
EP1621207A3 (en)	2006-11-22
CY1104971T1 (el)	2010-03-03
MXPA02010346A (es)	2004-09-06
JP2004500437A (ja)	2004-01-08
HUP0300560A2 (hu)	2003-06-28
SI21079B (sl)	2006-08-31
UA73566C2 (en)	2005-08-15
KR100849491B1 (ko)	2008-07-31
RU2002130719A (ru)	2004-03-27
NO20024988L (no)	2002-12-02
WO2001078761A3 (en)	2002-01-24
IS6581A (is)	2002-10-14
HUP0300560A3 (en)	2005-07-28
BG107203A (bg)	2003-05-30
ES2252227T3 (es)	2006-05-16
AU5832201A (en)	2001-10-30
EE200200596A (et)	2004-04-15

Publication	Publication Date	Title
US8771663B2 (en)	2014-07-08	Formulation having mobilising activity
JP4727988B2 (ja)	2011-07-20	エリスロポエチンの使用
DE60103052T2 (de)	2005-03-03	Verwendung von cxcr4 antagonisten zur behandlung von krebs und autoimmunkrankheiten
Steward et al.	1989	Recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) given as daily short infusions–a phase I dose-toxicity study
US20070258945A1 (en)	2007-11-08	G-GSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
JP2010235613A (ja)	2010-10-21	内皮前駆細胞の刺激並びに臓器の再生及び内臓障害の進行の抑制のための低用量エリスロポエチンの使用
SK14892002A3 (sk)	2003-06-03	Prípravok majúci mobilizačbú aktivitu
KR101192136B1 (ko)	2012-10-16	혈액 줄기 세포의 동원에 유효한 ｇ-ｃｓｆ와 ｐｌｇｆ의조합 약제
AU2001258322A1 (en)	2002-01-17	Formulation having mobilising activity
JPH11512747A (ja)	1999-11-02	造血幹細胞の動員方法
US20110076247A1 (en)	2011-03-31	Agent comprising g-csf for prevention and treatment of diabetic peripheral neuropathy
KR101144687B1 (ko)	2012-05-25	Ｇ－ｃｓｆ 를 함유하는 선유아세포 동원제 및 창상 치료제
Drapeau et al.	2012	The therapeutic potential of stimulating endogenous stem cell mobilization

Legal Events

Date	Code	Title	Description
2010-03-08	FB9A	Suspension of patent application procedure